Patient demographics in the clinical study
| Non-HFE (n=34) | HFE (n=12) | P value | |
| Mean age, years±SD | 70.06±8.48 | 70.95±6.54 | 0.483 |
| Sex, % (n) | 1.000 | ||
| Male | 82.35 (28) | 83.33 (10) | |
| Female | 17.65 (6) | 16.66 (2) | |
| Ethnicity, % (n) | 1.000 | ||
| Irish | 97.06 (33) | 100 (12) | |
| Other | 2.94 (1) | 0 (0) | |
| BCLC stage, % (n) | 1.000 | ||
| 0 | 26.47 (9) | 25 (3) | |
| A | 61.76 (21) | 66.67 (8) | |
| B | 11.76 (4) | 8.33 (1) | |
| ECOG score, % (n) | 1.000 | ||
| 0 | 97.06 (33) | 100 (12) | |
| 1 | 2.94 (1) | 0 (0) | |
| Cirrhosis, % (n) | 0.488 | ||
| Yes | 70.59 (24) | 58.33 (7) | |
| No | 29.41 (10) | 41.67 (5) | |
| Child-Pugh (if cirrhotic), % (n) | 0.492 | ||
| A | 79.17 (19) | 100 (7) | |
| B | 20.83 (5) | 0 (0) | |
| MELD (if cirrhotic) | 0.169 | ||
| Median | 8 | 7 | |
| Range | 7–14 | 6–9 | |
| AFP (kU/L) | 0.313 | ||
| Median | 5 | 4 | |
| Range | 1–132 | 1–310 | |
| Ferritin (µg/L) | 0.236 | ||
| Median | 93 | 73 | |
| Range | 10–417 | 14–2245 | |
| Therapy, % (n) | 0.502 | ||
| Resection | 50 (17) | 66.67 (8) | |
| Radiofrequency ablation | 50 (17) | 33.33 (4) | |
| Follow-up interval post diagnosis (months) | 0.379 | ||
| Median | 24.28 | 24.39 | |
| Range | 7.02–96.00 | 11.84–60.23 | |
| HFE diagnosis | |||
| Genetic | N/A | 6 | |
| Clinical | N/A | 5 | |
| Pathological | N/A | 1 | |
AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; HFE, haemochromatosis; MELD, Model for End-Stage Liver Disease; N/A, not available.